FLT3: ITDoes matter in leukemia

被引：392

作者：

Levis, M

Small, D

机构：

[1] Johns Hopkins Univ, Sch Med, Sidney Kimmel Comprehens Canc Ctr, Dept Oncol, Baltimore, MD 21231 USA

[2] Johns Hopkins Univ, Sch Med, Dept Pediat, Baltimore, MD 21231 USA

来源：

LEUKEMIA | 2003年 / 17卷 / 09期

关键词：

FLT3; AML; ITD; receptor tyrosine kinase; tyrosine kinase inhibitor;

D O I：

10.1038/sj.leu.2403099

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

FMS-like tyrosine kinase-3 (FLT3), a receptor tyrosine kinase, is important for the development of the hematopoietic and immune systems. Activating mutations of FLT3 are now recognized as the most common molecular abnormality in acute myeloid leukemia, and FLT3 mutations may play a role in other hematologic malignancies as well. The poor prognosis of patients harboring these mutations renders FLT3 an obvious target of therapy. This review summarizes the data on the molecular biology and clinical impact of FLT3 mutations, as well as the therapeutic potential of several small-molecule FLT3 inhibitors currently in development.

引用

收藏

页码：1738 / 1752

页数：15

相关论文

共 155 条

[91] Flt3 mutations from patients with acute myeloid leukemia induce transformation of 32D cells mediated by the Ras and STAT5 pathways [J].

Mizuki, M ;

Fenski, R ;

Halfter, H ;

Matsumura, I ;

Schmidt, R ;

Müller, C ;

Grüning, R ;

Kratz-Abers, K ;

Serve, S ;

Steur, C ;

Büchner, T ;

Kienast, J ;

Kanakura, Y ;

Berdel, WE ;

Serve, H .

BLOOD, 2000, 96 (12) :3907-3914

[92] Suppression of myeloid transcription factors and induction of STAT response genes by AML-specific Flt3 mutations [J].

Mizuki, M ;

Schwäble, J ;

Steur, C ;

Choudhary, C ;

Agrawal, S ;

Sargin, B ;

Steffen, B ;

Matsumura, I ;

Kanakura, Y ;

Böhmer, FD ;

Muller-Tidow, C ;

Berdel, WE ;

Serve, H .

BLOOD, 2003, 101 (08) :3164-3173

[93]

Moreno I, 2003, HAEMATOLOGICA, V88, P19

[94] Detection of FLT3 internal tandem duplication and D835 mutations by a multiplex polymerase chain reaction and capillary electrophoresis assay [J].

Murphy, KM ;

Levis, M ;

Hafez, MJ ;

Geiger, T ;

Cooper, LC ;

Smith, BD ;

Small, D ;

Berg, KD .

JOURNAL OF MOLECULAR DIAGNOSTICS, 2003, 5 (02) :96-102

[95] IDENTIFICATION OF A POINT MUTATION IN THE CATALYTIC DOMAIN OF THE PROTOONCOGENE C-KIT IN PERIPHERAL-BLOOD MONONUCLEAR-CELLS OF PATIENTS WHO HAVE MASTOCYTOSIS WITH AN ASSOCIATED HEMATOLOGIC DISORDER [J].

NAGATA, H ;

WOROBEC, AS ;

OH, CK ;

CHOWDHURY, BA ;

TANNENBAUM, S ;

SUZUKI, Y ;

METCALFE, DD .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1995, 92 (23) :10560-10564

[96] Molecular evolution of acute myeloid leukaemia in relapse:: unstable N-ras and FLT3 genes compared with p53 gene [J].

Nakano, Y ;

Kiyoi, H ;

Miyawaki, S ;

Asou, N ;

Ohno, R ;

Saito, H ;

Naoe, T .

BRITISH JOURNAL OF HAEMATOLOGY, 1999, 104 (04) :659-664

[97]

Nakao M, 1996, LEUKEMIA, V10, P1911

[98]

NEUBAUER A, 1994, BLOOD, V83, P1603

[99] Flt3 ligand can promote survival and macrophage development without proliferation in myeloid progenitor cells [J].

Nicholls, SE ;

Winter, S ;

Mottram, R ;

Miyan, JA ;

Whetton, AD .

EXPERIMENTAL HEMATOLOGY, 1999, 27 (04) :663-672

[100] Alterations of the FLT3 gene in acute promyelocytic leukemia: association with diagnostic characteristics and analysis of clinical outcome in patients treated with the Italian AIDA protocol [J].

Noguera, N ;

Breccia, M ;

Divona, M ;

Diverio, D ;

Costa, V ;

De Santis, S ;

Avvisati, G ;

Pinazzi, M ;

Petti, MC ;

Mandelli, F ;

Lo Coco, F .

LEUKEMIA, 2002, 16 (11) :2185-2189

← 5 6 7 8 9 10 11 12 13 14 →